CLAIMS

1. A composition for use in the treatment of ALS or a related disorder, comprising at least two drugs selected from acamprosate, baclofen, cinacalcet, mexiletine, sulfisoxazole and torasemide, or a salt, prodrug, derivative of any chemical purity, or sustained-release formulation thereof.

2. The composition for use of claim 1 comprising at least one of the following drug combinations:
   - baclofen and acamprosate,
   - baclofen and acamprosate and torasemide,
   - mexiletine and cinacalcet,
   - torasemide and baclofen,
   - baclofen and cinacalcet, or
   - torasemide and sulfisoxazole.

3. The composition for use of claim 1 or 2 further comprising riluzole, or a salt, prodrug, derivative of any chemical purity, or sustained-release formulation thereof.

4. The composition for use of any one of the preceding claims, which further comprises a pharmaceutically acceptable carrier or excipient.

5. The composition for use of any one of the preceding claims, wherein the compounds are formulated or administered together, separately or sequentially.

6. The composition for use of any one of the preceding claims, wherein said composition is administered repeatedly to the subject.

7. The composition for use of any one of claims 3 to 6, wherein riluzole is administered in a dosage from 0.1 to 50 mg per day.

8. The composition for use of any one of claims 1 to 7, wherein acamprosate, when present, is administered in a dosage of less than 50 mg per day, more preferably less than 10 mg per day.

9. The composition for use of any one of claims 1 to 8, wherein baclofen, when present, is administered in a dosage of less than 30 mg per day.

10. The composition for use of any one of the preceding claims, wherein said composition is administered orally.

11. The composition for use of any one of the preceding claims, wherein the combination of at least two drugs selected from the group consisting of acamprosate, baclofen, cinacalcet, mexiletine, sulfisoxazole and torasemide is administered orally and repeatedly every other day, in alternance with riluzole.

12. The composition for use of any one of the preceding claims, wherein the compounds are formulated together.

13. Riluzole, or a salt, prodrug, derivative of any chemical purity, or sustained-release formulation thereof, for use in combination with baclofen, or a salt, prodrug, derivative of any chemical purity, or sustained-release formulation thereof, and in further combination with a compound selected from acamprosate, cinacalcet, mexiletine, sulfisoxazole and torasemide, or a salt, prodrug, derivative of any chemical purity, or sustained-release formulation thereof, for treating ALS by combined, separate or sequential administration to a subject in need thereof.

CLAIMS

1. Use of a composition comprising acamprosate and baclofenor, or a salt, a prodrug, a derivative of any chemical purity or a sustained-release formulation thereof, in the manufacture of a medicament, for treating ALS or a related disorder in a subject in need thereof.

2. The use of claim 1, wherein the composition comprises at least one of the following drug combinations:
   - baclofen and acamprosate,
   - baclofen and acamprosate and torasemide or a salt, prodrug, derivative of any chemical purity, or sustained-release formulation thereof.

3. The use of claim 1 or 2, wherein the composition further comprises riluzole, or a salt, prodrug, derivative of any chemical purity, or sustained-release formulation thereof.

4. The use of any one of the preceding claims, wherein the medicament further comprises a pharmaceutically acceptable carrier or excipient.

5. The use of any one of the preceding claims, wherein the compounds of said composition are formulated or administered together, separately or sequentially.

6. The use of any one of the preceding claims, wherein said medicament is to be administered repeatedly to the subject.

7. The use of any one of claims 3 to 6, wherein riluzole is to be administered in a dosage from 0.1 to 50 mg per day.

8. The use of any one of claims 1 to 7, wherein acamprosate is to be administered in a dosage of less than 50 mg per day, more preferably less than 10 mg per day.

9. The use of any one of claims 1 to 8, wherein baclofen is to be administered in a dosage of less than 30 mg per day.

10. The use of any one of the preceding claims, wherein said medicament is to be administered orally.

11. The use of any one of the preceding claims, wherein said medicament is to be administered orally and repeatedly every other day, alternately with riluzole.

12. The use of any one of the preceding claims, wherein the compounds of said composition are formulated together.

13. Use of acamprosate, or a salt, a prodrug, a derivative of any chemical purity, or a sustained-release formulation thereof, in the manufacture of a medicament for treating ALS or a related disorder, wherein said medicament is to be administered in combination with baclofen, or a salt, prodrug, derivative of any chemical purity, or sustained-release formulation thereof.

14. Use of acamprosate, or a salt, a prodrug, a derivative of any chemical purity, or a sustained-release formulation thereof, in the manufacture of a medicament for treating ALS or a related disorder, wherein said medicament is to be administered in combination with baclofen and riluzole, or a salt, prodrug, derivative of any chemical purity, or sustained-release formulation thereof.